MENU
CHRS
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CHRS stock forecast, quote, news & analysis

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers... Show more

Industry: #Biotechnology
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
Nov 20, 2026

Why Coherus Oncology (CHRS) Stock Is Down -62% in the Last 30 Days

Key Takeaways

  • CHRS shares have fallen roughly 62% over the past 30 days, sliding from about $1.02 to near $0.39 as liquidity and dilution concerns intensified.
  • The selloff accelerated after third-quarter results, which included a revenue miss, lowered full-year LOQTORZI guidance, and a going-concern disclosure.
  • Management announced a roughly 30% workforce reduction and narrowed pipeline focus, lowering the quarterly LOQTORZI revenue needed to cover core costs to $25–$30 million.
  • LOQTORZI (toripalimab-tpzi) remains the company's only marketed product; third-quarter net sales rose 25% year over year but just 3% sequentially.
  • Encouraging tagmokitug plus toripalimab data in second-line esophageal cancer offered a pipeline offset but did not ease near-term balance-sheet worries.
  • For more detail on the company's outlook, explore CHRS Price Targets, Earnings, and Forecast pages.
  • Investors can also explore Trending AI Robots to see how AI-driven trading strategies are positioned across the market.

Coherus Oncology (CHRS) Company Overview and Market Position

Coherus Oncology, formerly known as Coherus BioSciences, is a U.S.-based commercial-stage biopharmaceutical company focused on immuno-oncology. Founded in 2010 and led by Chief Executive Officer Denny Lanfear, the company has moved away from its legacy biosimilar business—divesting products such as UDENYCA, Cimerli, and Yusimry—to concentrate on cancer immunotherapies. Its lead commercial asset is LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor approved for nasopharyngeal carcinoma. The clinical pipeline is anchored by tagmokitug, an investigational anti-CCR8 antibody, and casdozokitug, an anti-IL-27 antibody. Investors follow CHRS primarily for LOQTORZI's commercial ramp and the pipeline's clinical readouts, balanced against a cash-constrained balance sheet and execution risk.

Coherus Oncology (CHRS) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, CHRS has declined from approximately $1.02 to near $0.39, a drop of roughly 62%. Most of the move was concentrated in early-to-mid November following the company's third-quarter report. The longer-term trend is even steeper: shares traded near $1.32 in mid-August and now sit near $0.39, a decline of about 71% over the trailing quarter. The stock has been in a sustained downtrend through 2026, well below its 52-week high near $2.62, as persistent cash burn and financing overhang have outweighed clinical progress.

What Drove CHRS Stock Price in the Last 30 Days

The sharp decline was triggered by the company's third-quarter 2026 results, reported in early November. Coherus posted a non-GAAP loss of $0.20 per share on revenue of $14.27 million, short of the roughly $15.9 million consensus, with LOQTORZI net sales of $14.0 million. Management cut full-year LOQTORZI guidance to $54–$57 million from $57–$62 million and disclosed going-concern language in its quarterly filing, noting a cash runway of less than 12 months. Cash and investments fell to $83.6 million from $105.3 million at the end of the second quarter and $172.1 million at year-end.

To preserve capital, the company announced a roughly 30% workforce reduction, from about 140 to 100 employees, expected to save $6–$7 million per quarter, and refinanced its term loan, adding about $11.5 million in net cash. A $50 million at-the-market equity program established in August added to dilution concerns. Positive tagmokitug plus toripalimab data in second-line esophageal cancer—a 33.3% confirmed response rate—provided a clinical bright spot, but the balance-sheet narrative dominated investor sentiment.

What Drove CHRS Stock Performance Over the Last Quarter

The quarterly decline reflects a broader multi-month story of tightening liquidity. With LOQTORZI as its only marketed product and quarterly sales still well below breakeven, Coherus has relied on cost cuts and financing to extend its runway. Over the quarter, the company trimmed expenses, narrowed its pipeline toward esophageal cancer, and sought capital through equity and debt transactions. Although clinical signals from tagmokitug and casdozokitug kept the long-term thesis alive, repeated financing steps, missed revenue expectations, and the going-concern disclosure progressively reset the stock's valuation lower.

Trending AI Robots

Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader ecosystem of hundreds of bots trading thousands of tickers. Only top-performing and most relevant bots are featured, giving traders a filtered view of strategies that are currently standing out. The bots vary widely in strategy, timeframe, and performance metrics, so the section serves as a starting point for comparing different automated approaches across the market. Traders interested in systematic, data-driven strategies can explore the page to see how AI models are adapting to changing market conditions.

CHRS Stock Forecast Drivers: What Investors Should Watch Next

Investors should monitor several factors that could shape CHRS going forward. LOQTORZI's commercial execution is central, with management targeting roughly $15 million in fourth-quarter revenue and a path toward a $25–$30 million quarterly breakeven. Regulatory developments are also key: Coherus plans to meet with the FDA on tagmokitug dosing and a second-line esophageal cancer study design, with potential for an expedited or accelerated approval pathway. Balance-sheet items remain critical, including potential ex-U.S. partnering for tagmokitug, UDENYCA divestiture milestone payments, and any additional financing. With the stock trading below $1, listing-compliance considerations and ongoing cash-burn trends will also remain in focus.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for CHRS with price predictions
Nov 20, 2026

CHRS sees MACD Histogram just turned negative

CHRS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 30, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 49 instances where the indicator turned negative. In 46 of the 49 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CHRS as a result. In 74 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for CHRS entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +9.17% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHRS advanced for three days, in 182 of 239 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

CHRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.955) is normal, around the industry mean (3.596). P/E Ratio (-0.733) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.240) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (3.149) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 96 (best 1 - 100 worst), indicating slightly worse than average price growth. CHRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.24B. The market cap for tickers in the group ranges from 58 to 138.67B. VRTX holds the highest valuation in this group at 138.67B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -12%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -28%. VIVS experienced the highest price growth at 105%, while CUE experienced the biggest fall at -74%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 37%. For the same stocks of the Industry, the average monthly volume growth was 41% and the average quarterly volume growth was -10%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 44
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: -3 (-100 ... +100)
Why Coherus Oncology (CHRS) Stock Is Down -62% in the Last 30 Days